Mursla Bio

Mursla Bio is a Cambridge-based liquid biopsy company decoding cellular messengers to provide treatments for cancer. Its first-in-class in vitro diagnostic (IVD) blood test, based on artificial intelligence analysis of the multi-component content of liver-derived extracellular vesicles in blood, enables non-invasive liver biopsies at any time. Its flagship test aims to replace ultrasound in monitoring liver cancer among 10 million high-risk patients in Western countries.